Biomaterial Database

Immunohistochemical markers of prognostic value in surgical pathology. 1997

C R Taylor, and R J Cote

Immunohistochemical methods have enjoyed rapid growth in application and utility since their initial adaptation to paraffin sections 20 years ago. Initial applications were directed primarily to the identification of cell and tumor sub-types (lineage related markers). More recently immunohistochemical markers have been described that show great promise in determining tumor prognosis, at a very early stage of tumor development, independent of stage and grade. This review surveys the recent use of immunohistochemistry in prognosis, and offers some speculation as to areas of future promise.

UI	MeSH Term	Description	Entries
D007150	Immunohistochemistry	Histochemical localization of immunoreactive substances using labeled antibodies as reagents.	Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009369	Neoplasms	New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009374	Neoplasms, Experimental	Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.	Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011379	Prognosis	A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.	Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D015415	Biomarkers	Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc.	Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

C R Taylor, and R J Cote

[Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].

January 2002, Arkhiv patologii,

C R Taylor, and R J Cote

Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

September 2016, Journal of thoracic disease,

C R Taylor, and R J Cote

Prognostic Value of Immunohistochemical Markers for Locally Advanced Rectal Cancer.

January 2022, Molecules (Basel, Switzerland),

C R Taylor, and R J Cote

The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.

January 1996, European journal of cancer (Oxford, England : 1990),

C R Taylor, and R J Cote

The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.

October 2015, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,

C R Taylor, and R J Cote

Immunohistochemical prognostic markers in bladder cancer.

January 2002, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,

C R Taylor, and R J Cote

Prognostic value of clinical, pathological and immunohistochemical markers in stage II colon cancer patients.

January 2008, Acta chirurgica Iugoslavica,

C R Taylor, and R J Cote

Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers.

January 2018, Neuroendocrinology,

C R Taylor, and R J Cote

Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.

March 2010, Medical oncology (Northwood, London, England),